Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
23 06 2023
Historique:
received: 02 04 2022
accepted: 09 06 2023
medline: 26 6 2023
pubmed: 24 6 2023
entrez: 23 6 2023
Statut: epublish

Résumé

Colorectal cancers (CRCs) are prevalent worldwide, yet current treatments remain inadequate. Using chemical genetic screens, we identify that co-inhibition of topoisomerase I (TOP1) and NEDD8 is synergistically cytotoxic in human CRC cells. Combination of the TOP1 inhibitor irinotecan or its bioactive metabolite SN38 with the NEDD8-activating enzyme inhibitor pevonedistat exhibits synergy in CRC patient-derived organoids and xenografts. Mechanistically, we show that pevonedistat blocks the ubiquitin/proteasome-dependent repair of TOP1 DNA-protein crosslinks (TOP1-DPCs) induced by TOP1 inhibitors and that the CUL4-RBX1 complex (CRL4) is a prominent ubiquitin ligase acting on TOP1-DPCs for proteasomal degradation upon auto-NEDD8 modification during replication. We identify DCAF13, a DDB1 and Cullin Associated Factor, as the receptor of TOP1-DPCs for CRL4. Our study not only uncovers a replication-coupled ubiquitin-proteasome pathway for the repair of TOP1-DPCs but also provides molecular and translational rationale for combining TOP1 inhibitors and pevonedistat for CRC and other types of cancers.

Identifiants

pubmed: 37353483
doi: 10.1038/s41467-023-39374-9
pii: 10.1038/s41467-023-39374-9
pmc: PMC10290057
doi:

Substances chimiques

Topoisomerase I Inhibitors 0
pevonedistat S3AZD8D215
Proteasome Endopeptidase Complex EC 3.4.25.1
Ubiquitin 0
Ligases EC 6.-
Ubiquitin-Protein Ligases EC 2.3.2.27
DCAF13 protein, human 0
RNA-Binding Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

3762

Subventions

Organisme : Intramural NIH HHS
ID : Z01 BC006150
Pays : United States

Informations de copyright

© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Références

Mol Cancer Ther. 2022 Sep 6;21(9):1430-1438
pubmed: 35830858
Nat Commun. 2020 Mar 9;11(1):1274
pubmed: 32152270
Antioxid Redox Signal. 2010 Dec 1;13(11):1699-712
pubmed: 20486766
Nature. 2009 Apr 9;458(7239):732-6
pubmed: 19360080
Nat Protoc. 2012 Mar 01;7(3):594-605
pubmed: 22383038
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
Nat Rev Clin Oncol. 2017 Jul;14(7):417-433
pubmed: 28117417
Cell Death Differ. 2019 Jul;26(7):1251-1266
pubmed: 30283081
Nat Cell Biol. 2022 Jan;24(1):62-73
pubmed: 35013556
Front Mol Biosci. 2018 Mar 13;5:19
pubmed: 29594129
Nat Rev Cancer. 2006 Oct;6(10):789-802
pubmed: 16990856
J Biol Chem. 2005 Oct 28;280(43):36518-28
pubmed: 16141202
Annu Rev Biophys Biomol Struct. 1997;26:373-99
pubmed: 9241424
Cancer Treat Rev. 2006 Nov;32(7):491-503
pubmed: 16959432
Nat Rev Mol Cell Biol. 2015 Jan;16(1):30-44
pubmed: 25531226
Mol Cell. 2019 Feb 7;73(3):574-588.e7
pubmed: 30595436
Clin Cancer Res. 2018 Sep 1;24(17):4332-4345
pubmed: 29748182
Cancer Cell. 2021 Apr 12;39(4):566-579.e7
pubmed: 33848478
Nucleic Acids Res. 2015 Jan;43(2):987-99
pubmed: 25567988
Redox Biol. 2014 Jan 09;2:457-65
pubmed: 24624335
Chem Rev. 2009 Jul;109(7):2894-902
pubmed: 19476377
ACS Chem Biol. 2013 Jan 18;8(1):82-95
pubmed: 23259582
Genes Dev. 2011 Aug 1;25(15):1568-82
pubmed: 21828267
Clin Cancer Res. 2019 Nov 15;25(22):6581-6589
pubmed: 31227499
Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40
pubmed: 12042765
Mol Cell. 2007 Jun 22;26(6):775-80
pubmed: 17588513
Nat Chem Biol. 2017 Nov;13(11):1164-1171
pubmed: 28892090
Mech Ageing Dev. 2013 May-Jun;134(5-6):196-201
pubmed: 23571135
Nucleic Acids Res. 2017 May 5;45(8):4564-4576
pubmed: 28199696
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Chemother. 2016 Apr;28(2):74-82
pubmed: 26292710
Nucleic Acids Res. 2016 Apr 7;44(6):2816-26
pubmed: 26917015
Mol Cancer Ther. 2009 May;8(5):1008-14
pubmed: 19383846
Elife. 2016 Nov 17;5:
pubmed: 27852435
Nature. 2021 Aug;596(7873):583-589
pubmed: 34265844
Front Mol Biosci. 2022 Apr 06;9:871161
pubmed: 35463961
Front Mol Biosci. 2022 Sep 23;9:1007064
pubmed: 36213114
Cell. 2015 May 7;161(4):933-45
pubmed: 25957691
Cancer Res. 2010 Dec 15;70(24):10310-20
pubmed: 21159650
J Biol Chem. 2008 Jul 25;283(30):21074-83
pubmed: 18515798
EMBO Rep. 2008 Oct;9(10):969-76
pubmed: 18802447
Mol Cell Biol. 2013 Oct;33(20):4008-16
pubmed: 23938298
Mol Cell Biol. 2000 Jun;20(11):3977-87
pubmed: 10805740
Science. 1998 Mar 6;279(5356):1504-13
pubmed: 9488644
DNA Repair (Amst). 2020 May;89:102837
pubmed: 32200233
Trends Biochem Sci. 2012 Feb;37(2):66-73
pubmed: 22099186
Nucleic Acids Res. 2012 Aug;40(15):e119
pubmed: 22844090
Cell Rep. 2015 May 5;11(5):704-14
pubmed: 25921528
Nucleic Acids Res. 2002 Mar 1;30(5):1198-204
pubmed: 11861912
Open Biol. 2015 Apr;5(4):150018
pubmed: 25833379
J Cell Biol. 2014 Jan 20;204(2):231-45
pubmed: 24446482
Biochem J. 2008 May 1;411(3):523-30
pubmed: 18215123
J Biol Chem. 2009 Oct 9;284(41):28084-28092
pubmed: 19666469
Nat Protoc. 2006;1(6):2856-60
pubmed: 17406544
Mol Cell. 2013 Mar 7;49(5):897-907
pubmed: 23394999
Sci Rep. 2019 Apr 18;9(1):6278
pubmed: 31000741
Nat Commun. 2019 Jan 8;10(1):83
pubmed: 30622257
Nat Commun. 2020 Mar 12;11(1):1318
pubmed: 32165630
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
iScience. 2018 Dec 21;10:247-264
pubmed: 30553813
Cell Rep. 2016 Apr 12;15(2):300-9
pubmed: 27050524
Bioinformatics. 2016 Sep 15;32(18):2866-8
pubmed: 27153664
DNA Repair (Amst). 2020 Oct;94:102926
pubmed: 32674013
Cancer Treat Rev. 2017 Sep;59:54-60
pubmed: 28738235
Methods Mol Biol. 2018;1703:283-299
pubmed: 29177749
Nat Commun. 2021 Aug 18;12(1):5010
pubmed: 34408146
Nat Rev Mol Cell Biol. 2016 Nov;17(11):703-721
pubmed: 27649880
Annu Rev Plant Biol. 2011;62:299-334
pubmed: 21370976
Sci Adv. 2020 Nov 13;6(46):
pubmed: 33188014
Annu Rev Pharmacol Toxicol. 2006;46:189-213
pubmed: 16402903

Auteurs

Yilun Sun (Y)

Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA. yilun.sun@nih.gov.

Simone A Baechler (SA)

Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Xiaohu Zhang (X)

Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, USA.

Suresh Kumar (S)

Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Valentina M Factor (VM)

Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Yasuhiro Arakawa (Y)

Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Cindy H Chau (CH)

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Kanako Okamoto (K)

Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Anup Parikh (A)

Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Bob Walker (B)

Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Yijun P Su (YP)

Advanced Imaging and Microscopy Resource, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 20892, USA.

Jiji Chen (J)

Advanced Imaging and Microscopy Resource, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 20892, USA.

Tabitha Ting (T)

Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.

Shar-Yin N Huang (SN)

Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Erin Beck (E)

Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, USA.

Zina Itkin (Z)

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Crystal McKnight (C)

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Changqing Xie (C)

Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Nitin Roper (N)

Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Deepak Nijhawan (D)

Advanced Imaging and Microscopy Resource, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 20892, USA.

William Douglas Figg (WD)

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Paul S Meltzer (PS)

Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

James C Yang (JC)

Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Craig J Thomas (CJ)

Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, USA.

Yves Pommier (Y)

Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA. pommier@nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH